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, England. This study wahe aim of this study was to determine whether drug-eluting stents (DES) are superior to bare-metal stents
(BMS) in octogenarian patients with angina.Background Patients 80 years of age frequently have complex coronary disease warranting DES but have a higher risk
of bleeding from prolonged dual antiplatelet therapy.Methods This multicenter randomized trial was conducted in 22 centers in the United Kingdom and Spain. Patients80 years
of age underwent stent placement for angina. The primary endpoint was a 1-year composite of death, myocardial
infarction, cerebrovascular accident, target vessel revascularization, or major hemorrhage.Results In total, 800 patients (83.5  3.2 years of age) were randomized to BMS (n ¼ 401) or DES (n ¼ 399) for treatment
of stable angina (32%) or acute coronary syndrome (68%). Procedural success did not differ between groups
(97.7% for BMS vs. 95.4% for DES; p ¼ 0.07). Thirty-eight percent of patients had 2-vessel percutaneous coronary
intervention, and 66% underwent complete revascularization. Patients who received BMS had shorter stent implants
(24.0  13.4 mm vs. 26.6  14.3 mm; p ¼ 0.01). Rates of dual antiplatelet therapy at 1 year were 32.2%
for patients in the BMS group and 94.0% for patients in the DES group. The primary endpoint occurred in 18.7%
of patients in the BMS group versus 14.3% of patients in the DES group (p ¼ 0.09). There was no difference in death
(7.2% vs. 8.5%; p ¼ 0.50), major hemorrhage (1.7% vs. 2.3%; p ¼ 0.61), or cerebrovascular accident (1.2% vs.
1.5%; p ¼ 0.77). Myocardial infarction (8.7% vs. 4.3%; p ¼ 0.01) and target vessel revascularization (7.0% vs. 2.0%;
p ¼ 0.001) occurred more often in patients in the BMS group.Conclusions BMS and DES offer good clinical outcomes in this age group. DES were associated with a lower incidence
of myocardial infarction and target vessel revascularization without increased incidence of major hemorrhage.
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Abbreviations
and Acronyms
BMS = bare-metal stent(s)
CVA = cerebrovascular
accident
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TVR = target vessel
revascularization
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1372Improved health care has led to
an increase in the proportion of
elderly patients in the population.
As a consequence, patients are
presenting with stable coronary
disease and acute coronary
syndromes at a much older age,
and very elderly patients (age
>80 years) are an increasing slice
of day-to-day practice. Coronary
stenting is feasible for and bene-
ﬁcial to elderly patients with
anginal syndromes (1,2) but is
associated with higher complica-tion rates (3,4). Many trial protocols exclude elderly patients,
and the data for longer-term outcomes with intervention are
limited to retrospective analyses (5–9).
See page 1376
Elderly patients often have complex coronary artery
disease warranting use of drug-eluting stents (DES), but
prolonged dual antiplatelet therapy (DAPT) puts them at
higher risk for major bleeding complications (10).
Noncompliance with DAPT may also be more likely in
elderly patients, and this would put them at higher risk for
stent thrombosis (11–14).
We designed a prospective randomized trial to examine
the hypothesis that treatment of complex coronary disease
with DES in patients 80 years of age with angina would
prove superior to bare-metal stents (BMS) with respect to
a combined endpoint of mortality, myocardial infarction
(MI), target vessel revascularization (TVR), cerebrovascular
accident (CVA), or severe hemorrhage.
Methods
Patients 80 years of age were considered for the trial at
participating centers. Coronary disease warranting use of
DES (15 mm long or <3 mm wide) was a requirement.
Other subsets of disease that have a high risk of restenosis
(chronic total occlusions, bifurcations, left main stem disease)
were included. Second-generation everolimus-eluting stents
(Xience, Abbott Vascular, Santa Clara, California) and
bare-metal Vision stents (Abbott Vascular) were used.
Patients with non–ST-segment elevation myocardial
infarction, unstable angina, and stable angina were eligible to
participate in this study. Patients with acute ST-segment
elevation myocardial infarction, cardiogenic shock, throm-
bocytopenia (<50  109/mm3), poor life expectancy,
gastrointestinal hemorrhage 3 months, or previous intra-
cerebral bleeding were excluded.
Patients were randomized on a 1:1 basis using web-based
methodology. Before revascularization, all patients under-
went an assessment of angina status, angina medication,
physical examination, and measurement of creatine kinase/troponin levels. Techniques for stent deployment were left to
the discretion of the operator. Lesion preparation before
stent deployment was encouraged.
Before percutaneous coronary intervention (PCI), loading
doses of aspirin 300 mg and clopidogrel 600 mg were given
unless the patients were established on these drugs. Long-
term treatment with warfarin was not a contraindication,
but caution was emphasized. The use of glycoprotein IIb/IIIa
inhibitors was at the discretion of the operator, but cautionwas
urged.
Creatine kinase and troponin levels were measured 16 to
22 h after PCI. For patients receiving BMS, 1 month of
DAPT was mandatory. For patients receiving DES, DAPT
was prescribed for 1 year.
After discharge from the hospital, patients were followed
up at 6 months and 1 year to determine progress, drug
compliance, and clinical events. All clinical events were
adjudicated by an independent adjudication committee in
Spain and the United Kingdom (see the Online Appendix).
Deﬁnitions. Death was determined to be cardiac or
noncardiac. For patients with undetermined cause, the full
circumstances of demise were considered by the endpoints
committee before adjudication. MI was deﬁned using the
European Society of Cardiology/American College of Cardi-
ology Foundation/American Heart Association/World Heart
Federation 2007 deﬁnition (15). Bleeding endpoints were
deﬁned by the Thrombolysis In Myocardial Infarction classi-
ﬁcation (16) as none,minor, ormajor. TVRwas deﬁned as any
stented vessel requiring revascularization with balloon angio-
plasty, stenting, or coronary artery bypass graftingwithin 1 year
of the original procedure. CVA was deﬁned as a new neuro-
logical deﬁcit lasting >24 h conﬁrmed with appropriate
imaging abnormality. Stent thrombosis was deﬁned using the
Academic Research Consortium criteria (17).
Statistics and data management. The expected composite
primary endpoint rate for this group of patients treated with
BMS was estimated to be 20% at 1 year based on ARTS
(Arterial Revascularization Therapies Study) I and II (18,19).
We estimated the composite primary endpoint for the DES
group would be 12%. Using this estimate, a sample size of
658 patients would achieve 80% power to a 5% signiﬁcance
level. We were concerned about loss to follow-up in this age
group and therefore proposed to recruit 800 patients. Data
were collected on a dedicated web-based secure site, entered
by the host institution, and validated by the trial organiza-
tion (Sussex Cardiac Centre, Brighton, England, and RPS
Research Ibérica, Barcelona, Spain). All clinical events were
adjudicated by an independent committee using pre-deﬁned
endpoints. The Data and Safety Monitoring Committee was
responsible for the analysis of the data. All analyses were
based on an intention-to-treat principle.
Categorical variables are reported as frequencies and
percentages and compared using the chi-square test or, in
the case of low frequencies, the Fisher exact test. Continuous
variables are reported as mean  SD and compared using
the Student t test. Event-free survival was estimated using
Table 1
Demographic Data Comparing the Patients
Randomized to BMS or DES
BMS
(n ¼ 401)
DES
(n ¼ 399) p Value
Age (yrs) 83.4  3.1
(80–99)
83.6  3.2
(80–101)
0.35
Female 40.9 38.9 0.64
Diabetes 24.2 25.6 0.65
Hypertension 77.6 75.1 0.42
Hypercholesterolemia 52.9 57.6 0.17
Current smoker 4.0 5.0 0.49
Previous CVA/TIA 10.7 7.8 0.15
Peripheral vascular disease 12.5 10.3 0.33
Creatinine >200 mmol/l 7.0 6.0 0.57
Previous MI 21.5 29.8 0.007
Previous PCI 10.2 12.8 0.25
Previous CABG 4.2 7.0 0.088
Left ventricular function <40% 10.1 13.5 0.21
On warfarin pre-PCI 1.3 2.8 0.12
Values are mean  SD (range) or %. Patients randomized to the DES group were more likely to
have had a previous MI and previous CABG.
BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass graft; CVA ¼ cerebrovascular
accident; DES ¼ drug-eluting stent(s); MI ¼ myocardial infarction; PCI ¼ percutaneous coronary
intervention; TIA ¼ transient ischemic attack.
Table 3
The Primary Endpoint Was More Likely to Occur
in the BMS Group
Cause
Period
(months)
Vision BMS
(n ¼ 401)
Xience DES
(n ¼ 399) p Value
All-cause death 0–12 7.2% (29) 8.5% (34) 0.51
<1 1.2% (5) 1.5% (6) 0.77
1–6 2.7% (11) 3.3% (13) 0.68
6–12 3.2% (13) 3.8% (15) 0.71
Cardiac 0–12 4.7% (19) 3.3% (13) 0.37
<1 0.7% (3) 0.5% (2) 1.00
1–6 2.5% (10) 1.8% (7) 0.63
6–12 1.5% (6) 1.0% (4) 0.75
Noncardiac 0–12 2.5% (10) 5.3% (21) 0.045
<1 0.5% (2) 1.0% (4) 0.45
1–6 0.2% (1) 1.5% (6) 0.069
6–12 1.7% (7) 2.8% 0.48
Major hemorrhage 0–12 1.7% (7) 2.3% (9) 0.61
<1 0.7% (3) 0.5% (2) 1.00
1–6 0.7% (3) 0.8% (3) 1.00
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1373the Kaplan-Meier method and differences assessed using the
log-rank test. A value of p < 0.05 was used for statistical
signiﬁcance.
Results
Between 2009 and 2011, 800 octogenarian patients (400 in
the United Kingdom and 400 in Spain) were recruitedTable 2 Procedural Details Comparing the 2 Groups
BMS
(n ¼ 401)
DES
(n ¼ 399) p Value
Left main stem PCI 8.3 7.6 0.72
Left anterior descending PCI 63.0 60.7 0.50
Circumﬂex PCI 30.0 31.7 0.61
Right coronary artery PCI 35.3 38.1 0.41
Bypass graft PCI 1.5 3.6 0.067
Number of PCI vessels 0.71*
1 60.5 62.7
2 31.5 27.2
>2 8.0 10.2
Radial approach 58.2 52.4 0.12
Rotational atherectomy 12.0 9.5 0.26
Complete revascularization
planned
66.3 66.5 0.96
Staged procedure 7.3 8.3 0.28
Length of stent (mm) 24.0  13.4 26.6  14.3 0.011y
Number of stents deployed 2.0 (1–3) 2.0 (1–3) 0.32*
Correct stent deployed 95.0 93.9 0.73
Procedural success 97.7 95.4 0.075
Use of glycoprotein IIb/IIIa
inhibitors
1.7 1.5 0.79
Number of days in hospital 4 (1–8) 4 (1–8) 0.77*
Values are %, mean  SD, or median (interquartile range). The stent length was signiﬁcantly
greater in the DES group. Chi-square test was used for signiﬁcance unless otherwise stated. *Mann-
Whitney test. yTwo-sample Student t test.
Abbreviations as in Table 1.from 22 centers and randomized to BMS (n ¼ 401)
or DES (n ¼ 399). The clinical presentation was stable
angina (32.0%), troponin-negative acute coronary syndrome
(18.0%), and troponin-positive acute coronary syndrome
(50.0%).
Demographics are shown in Table 1 and demonstrate
that the groups were well matched. Procedural charac-
teristics are shown in Table 2. The only signiﬁcant
difference between the 2 groups was the slightly longer
stent length in the DES group. At 1 year, the rates of
DAPT for the 2 groups were 32.2% for BMS and 94.0%6–12 0.2% (1) 1.0% (4) 0.22
MI 0–12 8.7% (35) 4.3% (17) 0.014
<1 3.5% (14) 2.5% (10) 0.53
1–6 4.2% (17) 1.0% (4) 0.006
6–12 1.0% (4) 0.8% (3) 1.00
TVR 0–12 7.0% (28) 2.0% (8) 0.0009
<1 0.5% (2) 0.5% (2) 1.00
1–6 4.2% (17) 1.0% (4) 0.007
6–12 2.2% (9) 0.5% (2) 0.064
CVA 0–12 1.2% (5) 1.5% (6) 0.77
<1 0.7% (3) 0.0% (0) 0.25
1–6 0.0% (0) 1.0% (4) 0.061
6–12 0.5% (2) 0.5% (2) 1.00
Hemorrhagic 0–12 0.2% (1) 0.8% (3) 0.37
<1 0.0% (0) 0.0% (0) 1.00
1–6 0.0% (0) 0.3% (1) 0.50
6–12 0.2% (1) 0.55% (2) 0.62
Ischemic 0–12 1.0% (4) 0.8% (3) 1.00
<1 0.7% (3) 0.0% (0) 0.25
1–6 0.0% (0) 0.8% (3) 0.25
6–12 0.2% (1) 0.0% (0) 1.00
Primary endpoint 0–12 18.7% (75) 14.3% (57) 0.09
<1 5.5% (22) 4.5% (18) 0.63
1–6 7.5% (30) 5.35% (21) 0.25
6–12 5.7% (23) 4.5% (18) 0.52
Values are % (n). There was no signiﬁcant difference in mortality, major hemorrhage, and
permanent stroke between the 2 groups. There was an increased likelihood of MI and TVR in the
BMS group.
Abbreviations as in Table 1.
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1374for DES. Of the 6% not on DAPT in the DES group,
6 patients did not have a stent deployed for technical
reasons, 1 patient was noncompliant with all medication,
and the remaining 9 patients had DAPT withdrawn
because of clinical concerns (e.g., falls, easy bruising,
dyspeptic symptoms).
The primary endpoint and its components are shown in
Table 3. The cumulative primary endpoint of death/MI/
TVR/CVA/major hemorrhage was 18.7% in the BMS
group and 14.3% in the DES group (p ¼ 0.09). Death rates
were 7.2% for the BMS group (4.7% cardiac, 2.5%
noncardiac) and 8.5% for the DES group (3.3% cardiac,
5.3% noncardiac). Noncardiac deaths were chieﬂy attribut-
able to cancer (35%), infection (26%), or respiratory failure
(14%). Time to ﬁrst event is shown in the Kaplan-Meier
analysis in Figure 1.
Thrombolysis In Myocardial Infarction minor hemor-
rhage occurred in 2.0% of the BMS and 3.5% of the DES
group (p ¼ 0.20). There were 2 deﬁnite stent thromboses in
the DES group (one at 6 days and one at 115 days) and 2
probable stent thromboses (sudden cardiac death 2 days
after BMS implantation and 28 days after DES implanta-
tion). A forest plot analysis is shown in Figure 2. A table of
estimates of the odds ratio (with 95% conﬁdence intervals)
of the primary endpoint for all patients and various
subgroups is shown.
Discussion
This prospective randomized trial of octogenarian patients
undergoing stent placement for symptomatic coronary
disease showed that DES, when compared with BMS,
reduce the incidence of MI and TVR in the subsequent year.Figure 1 Kaplan-Meier Survival Plot
Kaplan-Meier survival plot for time to ﬁrst primary endpoint event for the DES and
BMS groups. BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s).There was no signiﬁcant difference in the incidence of death
from all causes, major hemorrhage, or CVA.
Elderly patients have more complex coronary disease. The
burden of disease is greater, and the nature of the coronary
disease (calciﬁcation and tortuosity in particular) is likely to
present more of a challenge to successful treatment. These
patients should therefore beneﬁt from DES technology, but
longer duration of DAPT puts these patients at higher risk
for bleeding (14). BMS have the advantage of reduced
DAPT and the limited functional signiﬁcance of vessel
restenosis in this more sedentary age group.
A potential confounder in this trial was the unpredictable
nature of mortality in this age group. Indeed, the DES
group had a signiﬁcantly higher rate of noncardiac mortality
than the BMS group, a ﬁnding that might have had an
important bearing on the primary endpoint.
A common clinical dilemma for elderly patients is
whether the risk of signiﬁcant hemorrhage with anticoagu-
lant or antiplatelet drugs is less than the risk of restenotic or
thrombotic events after stenting. For example, the Rockall
scoring system for the risk of rebleeding or death after
admission to hospital for acute gastrointestinal bleeding
gives 2 points for 80 years of age, 2 points for ischemic
heart disease, 2 points for blood seen on endoscopy, and
2 points if blood pressure is <100 mm Hg. A Rockall score
of 8 translates to a very high risk of mortality (20). Our study
is reassuring in that despite this anxiety, overall rates of
major hemorrhage have been remarkably low.
The risk of stroke was low and was not different between
the 2 groups. There was a prior concern that the risk of
intracerebral bleeding, either spontaneous or induced by
falls, would be greater in the DES group, but this did not
translate into an important clinical ﬁnding. Indeed, the rate
of stroke seen in this trial was no different than expected for
this age group.
Rates of MI and TVR were similar to those predicted
from the ARTS trials. The nature of the coronary disease in
this age group meant that there would be signiﬁcant in-stent
restenosis, but whether or not this would translate into rele-
vant clinical events was a doubt. Many of these patients had
signiﬁcant mobility limitations, but despite this, there was a
marked increase in clinical MI and TVR in the BMS group.
The forest plot analysis determined whether speciﬁc
pre-deﬁned subgroups had different results for the incidence
of primary outcomes. None of the groups analyzed showed
a beneﬁt for the BMS strategy. Of particular interest was the
reduction in primary endpoint events with the DES strategy
when using the radial artery for access or performing mul-
tivessel procedures.
Study limitations. The inclusion of all-cause mortality as
a primary endpoint was a potential confounder in the design
of the trial. We included it because the 2 groups of patients
had different antiplatelet regimens and there was a potential
for increased hemorrhagic deaths in the DES group. The
higher rate of noncardiac death in the DES group inﬂuenced
the ﬁnal result.
Figure 2
Forest Plot Determining the Odds Ratio of the
Primary Endpoint for Different Subgroups
There were no subgroups that had better outcomes with the BMS strategy. LMS ¼
left main stem disease; Rota ¼ rotational atherectomy; other abbreviations as in
Figure 1.
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1375A signiﬁcant proportion of patients undergoing implan-
tation of BMS were being treated for an acute coronary
syndrome. The protocol encouraged 1 month of DAPT, but
some investigators continued the use of DAPT for 1 year,
in line with guidelines for the treatment of acute coronary
syndromes. Our analysis of this cohort of patients showed no
signiﬁcant increase in bleeding for those treated for 1 month
or 1 year.
Conclusions
In patients 80 years of age undergoing stent placement for
symptomatic coronary disease, DES, when compared with
BMS, had no impact on all-cause death, CVA, and major
hemorrhage but reduced the incidence of MI and TVR.
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